OTCMKTS:AVMXY

AVITA MED LTD/S Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$7.89
0.00 (0.00 %)
(As of 11/27/2019)
Add
Compare
Today's Range
$7.89
$7.89
50-Day Range
$7.89
$7.89
52-Week Range
$1.06
$8.58
VolumeN/A
Average Volume183,275 shs
Market Capitalization$651.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28

Receive AVMXY News and Ratings via Email

Sign-up to receive the latest news and ratings for AVITA MED LTD/S and its competitors with MarketBeat's FREE daily newsletter.


About AVITA MED LTD/S

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.56 out of 5 stars

Medical Sector

3083rd out of 4,434 stocks

Biological Products, Except Diagnostic Industry

367th out of 422 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











AVITA MED LTD/S (OTCMKTS:AVMXY) Frequently Asked Questions

What stocks does MarketBeat like better than AVITA MED LTD/S?

Wall Street analysts have given AVITA MED LTD/S a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AVITA MED LTD/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are AVITA MED LTD/S's key executives?

AVITA MED LTD/S's management team includes the following people:
  • Dr. Michael S. Perry, CEO & Director (Age 60)
  • Mr. Timothy Rooney, Chief Admin. Officer & Interim CFO
  • Mr. Andrew Quick, Chief Technology Officer
  • Ms. Erin Liberto, Chief Commercial Officer
  • Mr. Adam Kelliher, Consultant

Who are some of AVITA MED LTD/S's key competitors?

What is AVITA MED LTD/S's stock symbol?

AVITA MED LTD/S trades on the OTCMKTS under the ticker symbol "AVMXY."

What is AVITA MED LTD/S's stock price today?

One share of AVMXY stock can currently be purchased for approximately $7.89.

How much money does AVITA MED LTD/S make?

AVITA MED LTD/S has a market capitalization of $651.87 million and generates $5.51 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does AVITA MED LTD/S have?

AVITA MED LTD/S employs 55 workers across the globe.

What is AVITA MED LTD/S's official website?

The official website for AVITA MED LTD/S is www.avitamedical.com.

Where are AVITA MED LTD/S's headquarters?

AVITA MED LTD/S is headquartered at 28159 Avenue Stanford Suite 220, Valencia CA, 91355.

How can I contact AVITA MED LTD/S?

AVITA MED LTD/S's mailing address is 28159 Avenue Stanford Suite 220, Valencia CA, 91355. The medical device company can be reached via phone at 661-367-9170 or via email at [email protected]


This page was last updated on 7/26/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.